Insilico Medicine and Liquid AI Partner to Develop Lightweight AI Models for Drug Discovery

Insilico Medicine and Liquid AI announced a partnership that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), available now – a single checkpoint trained to perform at state-of-the-art levels across multiple drug discovery subdomains, not a patchwork of separate point models.

The partnership tackles a critical challenge facing pharmaceutical companies today: how to harness cutting-edge AI capabilities without sending proprietary molecules, assays, and target data to external cloud services. By combining Liquid AI's efficient LFM architecture with Insilico's MMAI Gym, (a comprehensive training platform with over 1,000 pharmaceutical benchmarks), the work shows that on-premise deployment can deliver competitive results across the full spectrum of drug discovery tasks in a single system.

The model covers the complete discovery loop, spanning property prediction and ADMET endpoints, multi-parameter molecular optimization, target-aware scoring with protein-pocket conditioning, functional group reasoning, and retrosynthesis planning. Training involved approximately 120 billion tokens of pharmaceutical data across over two hundred different tasks.

"With LFM2-2.6B-MMAI, we've shown that efficient architecture design, not just scale, is what makes foundation models practical for the sciences. A single 2.6B-parameter model now matches or outperforms systems ten times its size across the drug discovery pipeline, all on private infrastructure. Our collaboration with Insilico is proof that you can reduce the cost of intelligence while raising the quality bar," says Ramin Hasani, CEO and co-founder of Liquid AI.